The finding marks an important step in the use of human induced pluripotent stem (iPS) cells for potentially treating neurological diseases such as Alzheimer's.
These iPS cells are derived from existing adult skin cells and show increasing utility as a promising approach for studying human disease and developing new therapies.
The study, led by researchers at University of California, Irvine (UCI) in the US, used a genetic process to reprogramme these cells into a pluripotent state capable of developing into any type of cell or tissue of the body.
The resulting cells act very much like human microglial cells.
In the brain, microglia mediate inflammation and the removal of dead cells and debris. These cells make up 10- to 15-per cent of brain cells and are needed for the development and maintenance of neural networks.
"Microglia play an important role in Alzheimer's and other diseases of the central nervous system. Recent research has revealed that newly discovered Alzheimer's-risk genes influence microglia behaviour," said Mathew Blurton-Jones, assistant professor at UCI Alzheimer's Disease Research Centre.
"Scientists have had to rely on mouse microglia to study the immunology of AD. This discovery provides a powerful new approach to better model human disease and develop new therapies," said Wayne Poon, a UCI MIND associate researcher.
Along those lines, the researchers examined the genetic and physical interactions between Alzheimer's disease pathology and iPS-microglia.
The study appears in the journal Neuron.
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
